Alzheimer's Medications Reduce Age-Related Macular Degeneration Risk: JAMA

Written By :  Jacinthlyn Sylvia
Medically Reviewed By :  Dr. Kamal Kant Kohli
Published On 2024-01-09 13:30 GMT   |   Update On 2024-01-09 13:31 GMT

A recent study found that medications used to treat Alzheimer's disease may hold promise in reducing the risk of age-related macular degeneration (AMD). The findings were published in the Journal of American Medical Association.Age-related macular degeneration is a significant threat to vision with inflammation in the macula believed to contribute to its development. Alzheimer's...

Login or Register to read the full article

A recent study found that medications used to treat Alzheimer's disease may hold promise in reducing the risk of age-related macular degeneration (AMD). The findings were published in the Journal of American Medical Association.

Age-related macular degeneration is a significant threat to vision with inflammation in the macula believed to contribute to its development. Alzheimer's disease medications, known as acetylcholinesterase inhibitors (AChEIs) with their anti-inflammatory properties was employed to explore whether these drugs could alter the risk of AMD.

This retrospective cohort study was conducted at healthcare facilities within the US Department of Veterans Affairs and spanned from January 2000 to September 2023. The study included a total of 21,823 veterans who were diagnosed with Alzheimer's disease between the ages of 55 and 80 without a preexisting AMD diagnosis in the Veterans Affairs database.

The exposure under scrutiny was the prescription of AChEIs for Alzheimer's treatment. The results unveiled through a propensity score-matched Cox model that indicated a critical association. For each additional year of AChEI treatment there was a 6% lower hazard of AMD observed as reflected in a hazard ratio of 0.94 (95% CI, 0.89-0.99).

This observational study presents a modest reduction in AMD risk among veterans with Alzheimer's disease who receive AChEIs. While these findings offer promise, the outcomes emphasize the need for caution and to underline the necessity of randomized clinical trials to establish a concrete cause-and-effect relationship. Further research is urged to explore these findings across diverse populations to validate their broad applicability.

This study highlight on a potential dual benefit of Alzheimer's medications and also sets the stage for more targeted investigations by potentially unlocking new avenues in the prevention and treatment of age-related macular degeneration.

Source:

Sutton, S. S., Magagnoli, J., Cummings, T. H., Hardin, J. W., & Ambati, J. (2024). Alzheimer Disease Treatment With Acetylcholinesterase Inhibitors and Incident Age-Related Macular Degeneration. In JAMA Ophthalmology. American Medical Association (AMA). https://doi.org/10.1001/jamaophthalmol.2023.6014

Tags:    
Article Source : JAMA Ophthalmology

Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News